The Global Health Body Issues Alert Over Acute Lack of Weight-Loss Medications

Fewer than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it releases its initial guidance on the drugs.

With over a billion individuals worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.

Based on projections, more than two billion could be obese by 2030 unless action is taken.

"The new guidance affirms that obesity is a lifelong illness that can be addressed with comprehensive and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are key hurdles to widespread access to the jabs that can help people shift significant weight, explains the organization.

Skinny Jab Scarcity

Despite the present most favorable outlook, the production of these medications might only reach approximately 100 million people – under 10% of those who need them, according to the health organization.

The advice calls on countries and companies to expand access, through approaches such as patent sharing.

The intellectual property rights on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.

How Weight-Loss Drugs Operate

GLP-1 drugs mimick a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals reduce food intake.

People commonly begin shedding pounds in the initial weeks of commencing the regular doses.

Research suggests people may see weight return after a year of discontinuing the drug, as their typical hunger come back.

Being carrying excess weight raises your chance for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.

Obesity concerns people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the WHO.